期刊
RADIATION ONCOLOGY
卷 16, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13014-020-01744-8
关键词
Recurrent-glioblastoma; FET-PET; Radiomics; Re-irradiation
资金
- Projekt DEAL
- Era PerMed
- Conselleria de Sanitat Universal i Salut Publica from the Comunitat Valenciana
- Else Kroner-Fresenius-Stiftung, Germany, within the EXCEL (Excellent Clinician Scientists in Freiburg - Education for Leadership) Program Immunological Causes and Therapies of Cancer
- Else-KroenerFresenius Research Foundation [2015_Kolleg.14]
The study evaluated the prognostic value of FET-PET radiomics in rGBM patients and found that radiomics features can effectively distinguish tumor and non-tumor tissues, with predictive value for time-to-progression, overall survival, and recurrence location.
Purpose The value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-positron emission tomography (PET)-radiomics in the outcome assessment of patients with recurrent glioblastoma (rGBM) has not been evaluated until now. The aim of this study was to evaluate whether a prognostic model based on FET-PET radiomics features (RF) is feasible and can identify rGBM patients that would most benefit from re-irradiation. Methods We prospectively recruited rGBM patients who underwent FET-PET before re-irradiation (GLIAA-Pilot trial, DRKS00000633). Tumor volume was delineated using a semi-automatic method with a threshold of 1.8 times the standardized-uptake-value of the background. 135 FET-RF (histogram parameters, shape and texture features) were extracted. The analysis involved the characterization of tumor and non-tumor tissue with FET-RF and the evaluation of the prognostic value of FET-RF for time-to-progression (TTP), overall survival (OS) and recurrence location (RL). Results Thirty-two rGBM patients constituted our cohort. FET-RF discriminated significantly between tumor and non-tumor. The texture feature Small-Zone-Low-Gray-Level-Emphasis (SZLGE) showed the best performance for the prediction of TTP (p = 0.001, satisfying Bonferroni-multiple-test significance level). Additionally, two radiomics signatures could predict TTP (TTP-radiomics-signature, p = 0.001) and OS (OS-radiomics-signature, p = 0.038). SZLGE and the TTP-radiomics-signature additionally predicted RL. Specifically, high values for TTP-radiomics-signature and for SZLGE indicated not only earlier progression, but also a RL within the initial FET-PET active volume. Conclusion Our findings suggest that FET-PET radiomics could contribute to the prognostic assessment and selection of rGBM-patients benefiting from re-irradiation. Trial registration DRKS00000633. Registered on 8th of December in 2010. .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据